Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.
Novasep has announced a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities at its Le Mans, France site, saying the move strengthens its position as a leading CDMO for the production of innovative...
The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m...
From operational uncertainty and outdated manual processes to new cell lines and a potential shift towards allogeneic cell therapy, CRB’s new report - Horizons: Cell and Gene Therapy - finds the biopharma industry at the critical intersection of obstacle...
Vibalogics has announced it is expanding its global footprint with a late phase clinical and commercial manufacturing facility near Boston, Massachusetts, a major milestone as it looks to advance its services to drug developers across the globe.
Fujifilm is boosting its gene therapy offering, taking the first steps to expand its viral vector contract development and manufacturing organization (CDMO) services to Europe, at the site of Fujifilm Diosynth Biotechnologies (FDB) in the North East of...
Catalent recently announced that it is investing US$130m in an expansion project at its viral vector manufacturing facility located in Harmans, Maryland, with five new manufacturing suites set to respond to a growing customer pipeline and market demand.
Increased manufacturing demands for cell and gene therapies drive the growth of the viral vector supply market, but challenges are still to be addressed, says Symbiosis.
In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.
Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.
Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.
GE Healthcare assigns Pharmadule Morimatsu to expand the offering of its ‘factory in a box’, known as KUBio, enabling the scale-up of biologics manufacture.